Table 1 Patient and treatment characteristics
From: Stereotactic radiation therapy for liver metastases: factors affecting local control and survival
Patients | ||
|---|---|---|
No. of patients evaluable/completing treatment | 74/76 | |
Gender | Male | 38 |
Female | 36 | |
Age at treatment (years) | Median | 61 (range 40-80) |
ECOG performance status | Median | 0 (range 0-2) |
0 | 50 | |
1 | 22 | |
2 | 2 | |
Status of extrahepatic disease | ||
NED (no evidence of disease) | 39 (53%) | |
SD/PD (stable/progressive) | 35 (47%) | |
Previous treatment per irradiated lesion | ||
No previous treatment | 23 (25.3%) | |
Chemotherapy | 44 (48.4%) | |
Endocrine therapy | 3 (3.3%) | |
Local therapy (surgery, radiofrequency ablation) | 4 (4.4%) | |
Combination of local and systemic treatment | 17 (18.6%) | |
Follow up (months) | Median | 15 (range 3-103) |
Primary tumor | Colorectal | 37 |
Breast | 12 | |
Esophageal | 5 | |
Stomach/Pancreas/Bile duct | 7 | |
Lung | 2 | |
Other | 11 | |
Lesions | ||
Total No. of lesions evaluated/treated | 91/95 | |
Lesions per patient | Mean | 1.23 (range 1-4) |
Total PTV dose at 60-95% IDL | Median | 35 (range 18-37.5) |
(Gy) | ||
Single PTV dose at 60-95% IDL | Median | 7 (range 5-12.5) |
(Gy) | ||
Fractions | Median | 5 (range 2-5) |
Minimum BED to GTV | Median | 91.2 Gy (18.7-183.5Gy) |
Gross tumor volume GTV (cc) | Median | 45 (range 1.3-699) |
<100 | 65 | |
100-200 | 12 | |
>200 | 12 | |
Planning target volume PTV (cc) | Median | 123 (range 10.6-1074) |